Alpine Immune Sciences

Creating novel protein-based immunotherapies to treat cancer and autoimmune disorders

Alpine Immune Sciences is developing next-generation immunotherapies to treat cancer and autoimmune disorders. Alpine’s proprietary technology platforms enable the development of engineered proteins optimized to modulate multiple immune cell receptors within the immune synapse. Alpine was founded by a veteran team of biotechnology executives and scientific experts with expertise in developing recombinant protein-based immunotherapies. The company has formed a research collaboration and license agreement with Kite Pharma to incorporate Alpine’s technology into Kite’s next generation of engineered T-cell therapies.

Reverse Merger in 2017 (NASDAQ: ALPN)
Year of Investment
Life Sciences
Seattle, Washington